fashion -WSS

fashion

author：hotspot 2025-09-30 00:02:51 - browse：9443

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： BridgeBio heart drug succeeds in pivotal study

WSS

Twill hunts for pharma partner to market its depression app

ALS groups 'won't be played again' by the FDA, drug sponsors

How to fix the rural physician shortage in the U.S.

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

A Q&A with Aletha Maybank, AMA’s chief health equity officer

International team creates first chimeric human

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Covid isolation guidance eased by the CDC

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why you get paid to donate plasma but not blood

The cancer drug shortage isn’t new — and neither are the solutions

Pfizer highlights cancer drugs it thinks could reignite investor interest

Malaria cases in Florida and Texas: Here’s what you need to know

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

United colonoscopy coverage change 'may cost lives,' doctors say

Flu vaccine offering decent levels of protection this winter, new data show

leisure time

Clinical trials giant ICON acquires HumanFirst

ALS groups 'won't be played again' by the FDA, drug sponsors

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

A look at other Americans who have crossed into North Korea over the years

ALS groups 'won't be played again' by the FDA, drug sponsors

knowledge

explore

focus

hotspot